AIM vs. ZIVO, EVAX, APTO, SNTI, BCLI, PMCB, TVGN, CRTX, NKGN, and COEP
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include ZIVO Bioscience (ZIVO), Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), Senti Biosciences (SNTI), Brainstorm Cell Therapeutics (BCLI), PharmaCyte Biotech (PMCB), Tevogen Bio (TVGN), Cortexyme (CRTX), NKGen Biotech (NKGN), and Coeptis Therapeutics (COEP). These companies are all part of the "medical" sector.
ZIVO Bioscience (NASDAQ:ZIVO) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.
ZIVO Bioscience has a net margin of -11,068.75% compared to ZIVO Bioscience's net margin of -16,123.32%. AIM ImmunoTech's return on equity of 0.00% beat ZIVO Bioscience's return on equity.
ZIVO Bioscience received 43 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 82.35% of users gave AIM ImmunoTech an outperform vote while only 61.11% of users gave ZIVO Bioscience an outperform vote.
In the previous week, AIM ImmunoTech had 7 more articles in the media than ZIVO Bioscience. MarketBeat recorded 9 mentions for AIM ImmunoTech and 2 mentions for ZIVO Bioscience. AIM ImmunoTech's average media sentiment score of 1.38 beat ZIVO Bioscience's score of -0.22 indicating that ZIVO Bioscience is being referred to more favorably in the media.
ZIVO Bioscience has higher earnings, but lower revenue than AIM ImmunoTech. ZIVO Bioscience is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
ZIVO Bioscience has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500.
12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 13.4% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
ZIVO Bioscience beats AIM ImmunoTech on 9 of the 15 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
